
NAD+
Nicotinamide adenine dinucleotide. Coenzyme in all living cells. Extensively studied for cellular energy metabolism and longevity.
Select Dosage
Quantity
Bundle & Save
Research Use Only. This product is intended for laboratory research purposes only. Not for human or veterinary use. Not for sale to minors.
NAD+ — Key Data
A snapshot of published research on NAD+. Each figure links to the literature summarized below.
How NAD+ Works
NAD+ is a coenzyme found in every living cell, serving as an electron carrier in mitochondrial energy production and a required substrate for sirtuins, PARP enzymes, and CD38. Cellular NAD+ levels decline 10-50% across all tissues during aging, driven primarily by a 2-3x increase in CD38 (the main NAD+ consumer). The correlation between CD38 and NAD+ levels is r = -0.99. For research use only.
Discovered 190610,000+ publicationsFirst described by Arthur Harden and William John Young as a cell-free fermentation factor
- 01
Sirtuin Activation
Primary- 3.5x SIRT3 activity when NAD+ levels are preserved
- SIRT1-7 require NAD+ as a co-substrate for deacetylation
- Sirtuin activity directly tracks available NAD+ levels
- 02
CD38 / NADase Axis
Primary- 2-3x CD38 protein increase with aging (all tissues)
- r = -0.99 correlation between CD38 and NAD+ levels
- CD38 knockout mice show no age-related NAD+ decline
- 03
PARP / DNA Repair
Secondary- PARP1 activation depletes NAD+ during DNA damage repair
- ~85% NAD+ reduction possible from sustained DNA repair activity
- PARP inhibition as alternative strategy to supplementation
What the Studies Show
Peer-reviewed outcomes from published NAD+ research.
0
750 mg infused over 6 hours in 8 subjects. No rise until after 2 hours (initial NAD+ consumed by liver). 538% urinary excretion increase. Liver function markers improved.
Grant et al., 2019Additional Clinical Outcomes
- 0Covarrubias et al., 2021
Human skin tissue. Subjects aged 61-77 vs 23-30. Brain decline 10-25%. Liver decline ~30%. 10-50% decline across all tissues measured.
- 0Igarashi et al., 2022
250 mg NMN daily for 12 weeks in older men (avg age 71). 1.45 to 1.60 m/s vs placebo decline. p = 0.015. Left grip strength also improved.
NAD+ Delivery Method Comparison
Grant et al., 2019 (8 subjects, 750mg over 6 hours)
Research Applications
Reported areas of investigation across the NAD+ literature.
- 01SIRTUIN ACTIVATION
Sirtuin-Dependent Longevity Pathways
All 7 sirtuins (SIRT1-7) require NAD+ as a co-substrate. Preserving NAD+ levels enables 3.5x SIRT3 activity for mitochondrial health.
- SIRT3 activity increase
- 3.5x
- Sirtuins requiring NAD+
- All 7
Study finding. Sirtuin activity directly tracks available NAD+ levels, making NAD+ the rate-limiting factor for longevity pathways.
- 02PHYSICAL FUNCTION
Gait Speed and Strength
Older men (avg age 71) showed 10% gait speed improvement and left grip strength gains with 250mg NMN daily for 12 weeks.
- Gait speed increase
- +10%
- Study duration
- 12 weeks
- Significance
- p = 0.015
Study finding. Gait speed: 1.45 to 1.60 m/s vs placebo decline. Left grip strength also improved.
Igarashi et al., 2022 - 03METABOLIC HEALTH
Plasma NAD+ Restoration
IV infusion of 750mg over 6 hours produced 398% plasma NAD+ increase with improved liver function markers.
- Plasma NAD+ increase
- +398%
- Urinary excretion increase
- +538%
Study finding. No rise until after 2 hours (initial NAD+ consumed by liver), then dramatic increase at 6 hours.
Grant et al., 2019
Reported Observations
- IV administration: flushing, nausea, chest tightness, mild GI discomfort (transient, dose-dependent)
- Subcutaneous: injection-site reactions reported
- No serious adverse events attributed to NAD+ in published clinical studies
This summary reflects observations from published peer-reviewed research. It is not a comprehensive safety assessment. Researchers should review primary literature before designing protocols. For Research Use Only.
Compound Profile
What Is NAD+?
Stability Information
- Protect from light and moisture
- Hygroscopic -- keep sealed
- Avoid repeated freeze-thaw cycles
Lyophilized
Up to 2 years
Reconstituted
Up to 7 days
Working solution
Use within 8 hours
References
Moghaddas et al., 2023
These references are provided for informational purposes. Kern is not affiliated with the authors or institutions listed above.
Related Products
Important Notice — Please Read
The statements made within this website have not been evaluated by the US Food and Drug Administration. The products we offer are not intended to diagnose, treat, cure, or prevent any disease. The peptides sold on this website are intended for research use only. The buyer is responsible for adhering to all local laws and regulations. Kern is not a pharmacy and does not provide medical advice or prescriptions. They are not for human consumption, are not FDA approved, and are not supplements or pharmaceutical drugs. The information provided on this website is for informational purposes and not a substitute for professional medical advice, diagnosis, or treatment. If you have questions or concerns about your health, please talk to your doctor. This site is an advertisement for education, research peptides, and not any specific medication. By purchasing from Kern, you confirm that you are a qualified researcher purchasing these compounds for legitimate in vitro or laboratory research purposes only. You must be 21 years of age or older to purchase.






